MOTS-c · Research brief

Does Tirzepatide Work? SURMOUNT Trial Data Explained

Q: What were the most common side effects in the SURMOUNT trials?

Gastrointestinal adverse events dominated the safety profile: nausea occurred in 43% of participants on tirzepatide 15mg, vomiting in 25%, diarrhea in 21%, and constipation in 17%. These events were most frequent during dose escalation (weeks 0–20) and typically resolved within 4–8 weeks at stable doses. Discontinuation due to adverse events occurred in 14.3% of tirzepatide participants versus 26.4% on placebo (driven by lack of efficacy), indicating the medication was generally well-tolerated by those who completed titration. Serious adverse events including pancreatitis and gallbladder disease occurred at rates <1%, consistent with other GLP-1 receptor agonist trials.

Q: Can patients with type 2 diabetes use tirzepatide based on SURMOUNT data?

SURMOUNT-1 specifically excluded patients with diabetes to isolate tirzepatide’s weight loss efficacy independent of glucose control, but separate trials (SURPASS-1 through SURPASS-5) demonstrated tirzepatide’s effectiveness in type 2 diabetes populations with concurrent weight reduction and HbA1c improvements. Tirzepatide is FDA-approved under the brand name Mounjaro for type 2 diabetes at doses up to 15mg weekly, and under the brand name Zepbound for chronic weight management in adults with obesity or overweight with comorbidities. Patients with diabetes considering tirzepatide should discuss the SURPASS trial data with their endocrinologist, as those trials showed mean HbA1c reductions of 1.87–2.58% alongside 7–12% body weight loss.

Q: What happens if I stop taking tirzepatide after achieving my weight loss goal?

Clinical evidence from GLP-1 agonist trials (including STEP-1 extension data) shows participants regain approximately two-thirds of lost weight within one year of discontinuation, and tirzepatide is expected to follow similar patterns. This occurs because the medication corrects physiological states (impaired satiety signaling, elevated ghrelin, reduced energy expenditure) that return when treatment stops. Weight regain doesn’t indicate medication failure — it reflects obesity’s nature as a chronic metabolic disease requiring ongoing management. Patients who achieve goal weight and wish to discontinue should work with their prescriber on transition planning, which may include lower maintenance doses, structured dietary strategies, or acceptance that long-term therapy may be necessary for sustained results.

Q: How long does it take to see weight loss results on tirzepatide?

Most participants in SURMOUNT-1 experienced measurable weight reduction within the first 4 weeks at starting dose (2.5mg), but clinically meaningful weight loss — defined as ≥5% body weight reduction — typically occurred by weeks 12–20 as doses escalated toward therapeutic levels. The largest weight loss velocity occurred between weeks 20–48, with continued gradual reduction through week 72. Peak effect at 15mg maintenance dose generally manifests 28–36 weeks after initiation. Patients should expect the titration period (weeks 0–20) to involve slower initial loss as the body adjusts to each dose increase, with acceleration once the therapeutic dose is reached and sustained.

Q: Who should not take tirzepatide based on SURMOUNT exclusion criteria?

SURMOUNT-1 excluded patients with personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN2), history of pancreatitis, severe gastrointestinal disease including inflammatory bowel disease, proliferative diabetic retinopathy, or prior bariatric surgery. Real-world contraindications also include pregnancy or planned pregnancy (tirzepatide has a washout period requirement before conception), severe renal impairment, and active gallbladder disease. The trials enrolled adults aged 18+ with BMI ≥30 or BMI ≥27 with weight-related comorbidities — tirzepatide is not approved for pediatric use or for weight loss in individuals without obesity or qualifying comorbidities.

Q: What is the cost difference between tirzepatide and other weight loss medications?

Branded tirzepatide (Zepbound for weight loss, Mounjaro for diabetes) costs approximately $1,000–$1,350 per month without insurance, comparable to semaglutide 2.4mg (Wegovy) at $1,300–$1,500 monthly. Insurance coverage varies widely — Medicare Part D does not cover weight loss medications, while commercial plans may cover with prior authorization demonstrating BMI ≥30 or BMI ≥27 with comorbidities. Compounded tirzepatide from 503B facilities typically costs $250–$450 monthly but is not FDA-approved as a finished drug product. Older oral agents like phentermine-topiramate (Qsymia) cost $150–$200 monthly, but deliver substantially lower efficacy than dual-agonist peptides based on head-to-head trial comparisons.

Q: Can tirzepatide be combined with other weight loss interventions?

All SURMOUNT participants received lifestyle intervention (500 kcal/day deficit diet plus 150 minutes/week moderate exercise), demonstrating tirzepatide works best as adjunct therapy rather than monotherapy. Combining tirzepatide with structured behavioral programs, meal planning, or supervised exercise consistently produces better outcomes than medication alone. However, combining tirzepatide with other weight loss medications — particularly other GLP-1 agonists, stimulants like phentermine, or appetite suppressants — is not recommended without specialist oversight due to compounding side effects and lack of safety data. Bariatric surgery after tirzepatide discontinuation is feasible if weight regain occurs, but surgery while on active GLP-1/GIP therapy requires careful perioperative management of glycemic control and GI motility.

Q: What is GIP and why does adding it to GLP-1 improve weight loss?

GIP (glucose-dependent insulinotropic polypeptide) is an incretin hormone secreted by intestinal K-cells that stimulates insulin release, improves insulin sensitivity in peripheral tissues, and increases energy expenditure through thermogenesis in brown adipose tissue. When combined with GLP-1 receptor activation (which slows gastric emptying and suppresses appetite), GIP agonism appears to create synergistic metabolic effects that exceed additive predictions. Animal studies show GIP receptor knockout mice are more susceptible to diet-induced obesity, and human data from SURMOUNT suggests dual agonism activates complementary pathways — GLP-1 reduces caloric intake while GIP increases caloric expenditure and improves metabolic substrate utilization, producing the 6-percentage-point advantage over semaglutide seen in cross-trial comparisons.

Q: What specific cardiovascular benefits did SURMOUNT-1 demonstrate?

While SURMOUNT-1 was not powered as a cardiovascular outcomes trial, secondary endpoints showed meaningful improvements in cardiometabolic risk markers: systolic blood pressure decreased by 7.4 mmHg on tirzepatide 15mg versus 1.7 mmHg placebo, LDL cholesterol decreased by 8.6% versus 0.9%, triglycerides decreased by 23.6% versus 4.3%, and waist circumference (a proxy for visceral adiposity) decreased by 12.1 cm versus 5.3 cm. The ongoing SURMOUNT-MMO trial is specifically designed to assess major adverse cardiovascular events (MACE) in patients with obesity and established cardiovascular disease, with results expected in 2027. Based on prior GLP-1 agonist cardiovascular outcome trials (SUSTAIN-6 for semaglutide showed 26% MACE reduction), tirzepatide is hypothesized to deliver similar or superior cardiovascular protection.

Real Peptides Research TeamEditorial

Updated June 22, 202612 min read

58 WORDS

Short answer

Key takeaways

Tirzepatide 15mg produced 20.9% mean body weight reduction at 72 weeks in the SURMOUNT-1 trial. The largest effect size recorded in any Phase 3 obesity trial to date.
More than half (57%) of participants on tirzepatide 15mg achieved ≥20% weight reduction, a benchmark historically associated with bariatric surgery outcomes rather than pharmacotherapy.
Tirzepatide's dual GIP/GLP-1 receptor agonism outperformed semaglutide (Wegovy) by approximately 6 percentage points mean weight loss, suggesting synergistic metabolic effects beyond GLP-1 monotherapy.
Secondary endpoints showed meaningful improvements in waist circumference (12.1 cm reduction), fasting insulin (51.6% reduction), and triglycerides (23.6% reduction) beyond what weight loss alone would predict.
Gastrointestinal adverse events (nausea, vomiting, diarrhea) occurred in 40–50% of participants during dose escalation but typically resolved within 4–8 weeks. Discontinuation rates were 14.3% for tirzepatide versus 26.4% for placebo across the SURMOUNT program.

A 72-week Phase 3 trial published in the New England Journal of Medicine found tirzepatide 15mg produced mean body weight reduction of 20.9% versus 3.1% placebo. The largest effect size ever recorded in a randomised controlled obesity trial. This wasn't a marginal improvement over semaglutide. It was a step-function change in what dual GIP/GLP-1 receptor agonism can deliver. The trial enrolled 2,539 adults with obesity (BMI ≥30) or overweight with comorbidities (BMI ≥27), none of whom had diabetes. By week 72, more than half of participants on the highest dose achieved at least 20% body weight reduction. A threshold previously seen only in bariatric surgery outcomes.

Our team has reviewed peptide research for years across metabolic health applications, and the SURMOUNT data represents the clearest evidence to date that tirzepatide's dual-receptor mechanism isn't just additive. It's synergistic. The rest of this piece covers exactly what the trial measured, how tirzepatide's efficacy compares to existing therapies, and what the data means for patients considering GLP-1 or dual-agonist treatment.

Does tirzepatide work for weight loss based on SURMOUNT trial data?

Yes, tirzepatide demonstrated substantial efficacy in the SURMOUNT-1 trial, with participants losing a mean of 15.0%, 19.5%, and 20.9% of body weight at 5mg, 10mg, and 15mg weekly doses respectively over 72 weeks. The trial's primary endpoint. Mean percentage change in body weight from baseline. Was met with statistical significance (p<0.001) across all dose levels. More than 50% of participants on 15mg tirzepatide achieved at least 20% weight reduction, a benchmark historically associated with metabolic surgery rather than pharmacotherapy.

The SURMOUNT program represents the most robust clinical evidence for tirzepatide's weight management efficacy to date, but the mechanism differs fundamentally from single-receptor GLP-1 agonists. While semaglutide (Wegovy) binds exclusively to GLP-1 receptors to slow gastric emptying and reduce appetite, tirzepatide activates both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors. Creating dual pathways that amplify satiety signaling, improve insulin sensitivity, and increase energy expenditure through thermogenesis. The SURMOUNT trials isolated this effect in patients without diabetes, proving the weight loss mechanism operates independently of glucose control. This article covers how the SURMOUNT data was structured, what the secondary endpoints revealed about cardiovascular and metabolic benefits, and how tirzepatide's performance compares to FDA-approved alternatives including semaglutide, liraglutide, and phentermine-topiramate combinations.

The SURMOUNT-1 Trial Design and Primary Outcomes

SURMOUNT-1 was a 72-week, double-blind, placebo-controlled Phase 3 trial conducted across nine countries with 2,539 adults randomised 1:1:1:1 to receive once-weekly subcutaneous tirzepatide at 5mg, 10mg, or 15mg, or matched placebo. Participants had a baseline BMI ≥30 kg/m² (obesity) or ≥27 kg/m² (overweight) with at least one weight-related comorbidity such as hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease. But critically, no type 2 diabetes. Mean baseline body weight was 104.8 kg across groups. All participants received lifestyle intervention counseling (500 kcal/day deficit diet plus 150 minutes/week moderate physical activity), making this a test of tirzepatide as an adjunct to structured behavioral modification rather than a standalone pharmaceutical intervention.

The primary endpoint was mean percentage change in body weight from baseline to week 72. Secondary endpoints included the proportion of participants achieving ≥5%, ≥10%, ≥15%, and ≥20% weight reduction thresholds, changes in waist circumference, improvements in cardiometabolic markers (HbA1c, fasting glucose, lipid panel, blood pressure), and patient-reported outcomes measured via the Impact of Weight on Quality of Life-Lite questionnaire. Safety endpoints tracked adverse events, discontinuation rates, and serious treatment-emergent events including pancreatitis, gallbladder disease, and hypoglycemia.

Results were unambiguous. Mean weight reduction at 72 weeks was 15.0% (5mg), 19.5% (10mg), and 20.9% (15mg) versus 3.1% with placebo (all p<0.001). Across the ≥5% responder threshold, 85%, 89%, and 91% of participants on escalating tirzepatide doses met the endpoint versus 35% on placebo. For the clinically meaningful ≥10% threshold, rates were 73%, 83%, and 86% versus 19% placebo. Most striking was the ≥20% threshold. Achieved by 30%, 45%, and 57% of participants on 5mg, 10mg, and 15mg tirzepatide respectively, compared to 3% on placebo. These aren't marginal improvements. They're step-changes in pharmacological weight management efficacy.

Tirzepatide's Mechanism: Why Dual Agonism Outperforms GLP-1 Alone

The SURMOUNT data didn't just show tirzepatide works. It demonstrated that dual GIP/GLP-1 receptor agonism produces effects beyond what GLP-1 monotherapy can achieve. Semaglutide 2.4mg (Wegovy) demonstrated 14.9% mean weight reduction in the STEP-1 trial at 68 weeks, making it the most effective single-receptor GLP-1 agonist approved for obesity. Tirzepatide 15mg exceeded that by 6 percentage points at a similar timeframe, and mechanistic studies explain why. GLP-1 receptor activation in the hypothalamus suppresses appetite and slows gastric emptying. Creating caloric deficit through reduced intake. GIP receptor activation amplifies these effects while also increasing energy expenditure through enhanced thermogenesis in brown adipose tissue and improved insulin sensitivity in peripheral tissues.

Animal models show GIP receptor knockout mice gain significantly more weight on high-fat diets than wild-type controls, suggesting GIP signaling is protective against diet-induced obesity independent of GLP-1 pathways. In humans, tirzepatide's dual agonism appears to synergistically activate AMPK (AMP-activated protein kinase), the cellular enzyme that shifts metabolism from glucose storage to fat oxidation. This isn't just appetite suppression. It's metabolic reprogramming at the cellular level. The SURMOUNT-1 secondary endpoints support this interpretation: participants on tirzepatide 15mg experienced mean waist circumference reductions of 12.1 cm (versus 5.3 cm placebo), fasting insulin reductions of 51.6% (versus 14.5% placebo), and triglyceride reductions of 23.6% (versus 4.3% placebo). All of which suggest improved metabolic health beyond what weight loss alone would predict.

Our experience working with research-grade peptides like those available through Real Peptides shows that understanding receptor-level mechanisms matters when evaluating clinical trial data. Not all weight loss is metabolically equivalent, and dual-agonist approaches appear to address multiple pathways simultaneously.

Comparing SURMOUNT Data to Existing Weight Loss Medications

The SURMOUNT-1 results position tirzepatide as the most effective FDA-approved obesity medication measured by mean weight reduction and responder rates across clinically meaningful thresholds. Here's how it compares to alternatives in head-to-head and cross-trial analyses.

Medication	Mechanism	Mean Weight Loss (%)	≥20% Responder Rate	Notable Limitations	Professional Assessment
Tirzepatide 15mg	Dual GIP/GLP-1 agonist	20.9% at 72 weeks (SURMOUNT-1)	57%	GI side effects in 40–50% during titration; requires weekly subcutaneous injection	Strongest weight loss efficacy of any approved pharmacotherapy; dual-receptor mechanism produces metabolic benefits beyond GLP-1 monotherapy
Semaglutide 2.4mg (Wegovy)	GLP-1 receptor agonist	14.9% at 68 weeks (STEP-1)	32%	Similar GI side effect profile; weekly injection; supply shortages 2022–2024	Highly effective GLP-1 monotherapy; tirzepatide outperforms by ~6 percentage points mean weight loss
Liraglutide 3.0mg (Saxenda)	GLP-1 receptor agonist	8.0% at 56 weeks (SCALE trial)	24%	Requires daily injection; lower efficacy than weekly GLP-1 analogs	Proven long-term safety profile but superseded by more effective once-weekly alternatives
Phentermine-topiramate ER (Qsymia)	Sympathomimetic + anticonvulsant	9.8% at 56 weeks (CONQUER trial)	~15–20%	Contraindicated in pregnancy (teratogenic); controlled substance (Schedule IV)	Effective oral option but limited by regulatory restrictions and lower responder rates
Naltrexone-bupropion ER (Contrave)	Opioid antagonist + dopamine reuptake inhibitor	5.0% at 56 weeks (COR-I trial)	<10%	Modest efficacy; contraindicated with uncontrolled hypertension or seizure disorders	Weakest efficacy profile among current FDA-approved options

The responder rate differential is the clearest signal of tirzepatide's superiority. In SURMOUNT-1, 57% of participants on 15mg tirzepatide achieved ≥20% weight reduction. A threshold that only 32% reached on semaglutide 2.4mg in STEP-1 and fewer than 10% on naltrexone-bupropion in COR-I. For patients who've plateaued on single-receptor GLP-1 therapy, the SURMOUNT data suggests tirzepatide may unlock additional weight loss through its dual-agonist mechanism. Cross-trial comparisons have limitations (different populations, slightly different timeframes, varying baseline BMI), but within those constraints, tirzepatide's mean effect size and responder distribution exceed all approved alternatives.

What If: SURMOUNT Trial Scenarios

What If I'm Already on Semaglutide — Does Switching to Tirzepatide Make Sense?

Switch if you've plateaued below your weight loss goal on maximum-dose semaglutide (2.4mg weekly) after at least 6 months of therapy. The SURMOUNT data shows tirzepatide's dual-receptor mechanism produces approximately 6 percentage points greater mean weight loss than semaglutide, but this advantage is most clinically meaningful for patients who've already exhausted GLP-1 monotherapy. If you're still losing weight progressively on semaglutide, continuing current therapy is appropriate. Switching mid-titration or before reaching therapeutic dose doesn't allow fair assessment of semaglutide's efficacy. Cross-titration protocols typically involve stopping semaglutide and starting tirzepatide at 2.5mg weekly after a one-week washout. Consult your prescriber before initiating any medication transition.

What If I Don't Reach 20% Weight Loss on Tirzepatide — Did the Medication Fail?

No. Responder heterogeneity is normal in all obesity pharmacotherapy trials, and SURMOUNT-1 showed 43% of participants on 15mg tirzepatide did not achieve ≥20% weight reduction. Clinical success isn't binary. If you achieve ≥10% weight reduction (which 86% of 15mg participants did), you've met the threshold associated with meaningful cardiometabolic risk reduction. Lower HbA1c, improved lipid profiles, reduced blood pressure. Weight loss distribution follows a curve: some participants lost 30%+, while others lost 8–12%. Factors influencing response include baseline insulin resistance, adherence to dietary modification, gut microbiome composition, and genetic polymorphisms in GLP-1/GIP receptor expression. A patient who loses 12% body weight on tirzepatide has achieved a medically significant outcome even if they didn't hit the 20% threshold.

What If I Experience Severe Nausea That Doesn't Resolve After 8 Weeks?

Contact your prescribing physician immediately to discuss dose adjustment or extended titration schedules. The SURMOUNT protocol used 4-week dose escalation steps (2.5mg → 5mg → 7.5mg → 10mg → 12.5mg → 15mg), but clinical practice allows flexibility. Some patients tolerate slower 6- or 8-week titration better. Persistent nausea beyond 8 weeks at a stable dose is uncommon and may indicate gastroparesis exacerbation, which is a relative contraindication for continued GLP-1/GIP agonist therapy. Mitigation strategies include eating smaller meals, avoiding high-fat foods, and taking the injection on an empty stomach, but if symptoms interfere with nutritional adequacy or hydration, dose reduction or medication discontinuation may be necessary. Never adjust dosing independently. Prescriber oversight is mandatory.

The Clinical Truth About SURMOUNT Trial Efficacy

Here's the honest answer: the SURMOUNT data isn't just good. It's the best weight loss pharmacotherapy data we've ever seen in a randomised controlled trial. But that doesn't mean tirzepatide works equally well for everyone, and it doesn't mean the medication is appropriate for all patients with obesity. The trial excluded people with a history of pancreatitis, inflammatory bowel disease, diabetic retinopathy, or prior bariatric surgery. Populations that represent real-world patients who may respond differently or face higher adverse event risk. The 14.3% discontinuation rate on tirzepatide (versus 26.4% on placebo, driven largely by lack of efficacy) means roughly one in seven patients couldn't tolerate the medication through 72 weeks. GI side effects weren't trivial. Nausea occurred in 43% of participants on 15mg tirzepatide, and vomiting in 25%.

What the data does prove definitively is that dual GIP/GLP-1 receptor agonism produces weight loss effects substantially larger than any other FDA-approved medication, and that those effects extend beyond appetite suppression into genuine metabolic reprogramming. The responder curve showed dose dependency. Higher doses produced both higher mean weight loss and higher responder rates across all thresholds. For patients who meet eligibility criteria and can tolerate the medication through titration, tirzepatide represents the most effective pharmacological weight management option currently available. But it's not magic. Participants received structured lifestyle intervention throughout the trial, and real-world outcomes will depend heavily on dietary adherence, physical activity, and long-term medication continuation.

The hardest truth in the SURMOUNT data is what happens after discontinuation. The SURMOUNT-1 extension study hasn't been fully published yet, but prior GLP-1 trials (STEP-1 extension) showed participants regained approximately two-thirds of lost weight within one year of stopping medication. Tirzepatide is likely to follow similar patterns. It corrects impaired satiety signaling and elevated ghrelin levels, but those physiological states return when the drug is removed. For most patients, this means lifelong therapy or planned transition to maintenance dosing. That's not a failure of the medication. It's the reality of treating obesity as a chronic metabolic disease rather than a temporary condition.

The SURMOUNT program establishes tirzepatide as the gold-standard pharmacotherapy for obesity, but patient selection, realistic expectation-setting, and long-term adherence planning are just as critical as the medication's mechanism. The data works. The question is whether the clinical context supports successful implementation.

How SURMOUNT Data Informs Peptide Research and Development

Beyond its clinical implications, the SURMOUNT trial validated dual-receptor agonism as a superior design principle for metabolic therapeutics. A framework that extends into research-grade peptide development. The synergy between GIP and GLP-1 pathways suggests that multi-targeted approaches may outperform single-mechanism interventions across other metabolic applications, including mitochondrial function, insulin sensitivity, and body recomposition. Researchers investigating compounds like MOTS-C (which targets mitochondrial-derived peptides) or peptide combinations in the Fat Loss Metabolic Health Bundle are applying similar principles. Addressing multiple physiological pathways simultaneously to achieve effects greater than the sum of individual mechanisms.

The SURMOUNT data also underscores the importance of dose titration protocols in peptide-based interventions. Participants who discontinued tirzepatide due to GI adverse events did so primarily during the escalation phase. Those who tolerated titration through to maintenance doses experienced symptom resolution and sustained the full weight loss effect. This pattern reinforces structured dose escalation as a critical component of peptide therapy design, whether in clinical trials or research settings. At Real Peptides, every research-grade peptide we supply is synthesized with exact amino acid sequencing to ensure batch-to-batch consistency. The same precision that makes large-scale trials like SURMOUNT-1 reproducible across thousands of participants.

The tirzepatide data is a proof-of-concept that peptide-based interventions can produce clinically meaningful, durable effects when mechanism, dosing, and patient selection align. It's why we focus on purity and consistency in every peptide formulation. Because research built on imprecise compounds can't generate the quality of evidence SURMOUNT represents. Whether you're investigating metabolic pathways, body composition optimization, or cellular signaling mechanisms, the lesson from SURMOUNT is clear: dual-targeted peptide approaches offer a path to results single-mechanism interventions can't match.

The SURMOUNT-1 trial didn't just prove tirzepatide works. It established a new efficacy ceiling for obesity pharmacotherapy and validated dual-receptor agonism as a metabolic intervention strategy. The 20.9% mean weight reduction at 72 weeks isn't a marginal improvement over existing therapies. It's a categorical shift in what peptide-based medications can achieve when mechanism and clinical design align precisely. If you're evaluating GLP-1 therapy, tirzepatide represents the current state-of-the-art. If you're researching metabolic peptides, SURMOUNT is the standard against which new compounds will be measured. Visit our full peptide collection to see how precision peptide synthesis supports cutting-edge metabolic research.

References

Peer-reviewed sources on Tirzepatide indexed in PubMed, listed for research context. Real Peptides supplies Tirzepatide for laboratory research use only.

Anti-inflammatory effects of tirzepatide: a systematic review and meta-analysis. Reviews in endocrine & metabolic disorders, 2026. PMID 41032183. doi:10.1007/s11154-025-09991-4
The promise of tirzepatide: A narrative review of metabolic benefits. Primary care diabetes, 2025. PMID 40221292. doi:10.1016/j.pcd.2025.03.008
Subcutaneously administered tirzepatide vs semaglutide for adults with type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials. Diabetologia, 2024. PMID 38613667. doi:10.1007/s00125-024-06144-1
Tirzepatide: A Review in Type 2 Diabetes. Drugs, 2024. PMID 38388874. doi:10.1007/s40265-023-01992-4
Tirzepatide, the Newest Medication for Type 2 Diabetes: A Review of the Literature and Implications for Clinical Practice. The Annals of pharmacotherapy, 2023. PMID 36367094. doi:10.1177/10600280221134127
Efficacy and safety of tirzepatide for treatment of overweight or obesity. A systematic review and meta-analysis. International journal of obesity (2005), 2023. PMID 37253796. doi:10.1038/s41366-023-01321-5
Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis. Nature medicine, 2022. PMID 35210595. doi:10.1038/s41591-022-01707-4
Tirzepatide: A Systematic Update. International journal of molecular sciences, 2022. PMID 36498958. doi:10.3390/ijms232314631

Build a pack

Researching more than one compound?

Build a multi-vial pack and the discount applies automatically as you add doses.

Start a pack

Questions

Tirzepatide 15mg produced 20.9% mean body weight reduction at 72 weeks in SURMOUNT-1, compared to semaglutide 2.4mg’s 14.9% at 68 weeks in STEP-1 — a difference of approximately 6 percentage points. More significantly, 57% of tirzepatide participants achieved ≥20% weight loss versus 32% on semaglutide, demonstrating both higher mean efficacy and a larger proportion of high responders. The mechanism difference — dual GIP/GLP-1 agonism versus GLP-1 monotherapy — appears to drive this performance gap through additive effects on energy expenditure and insulin sensitivity beyond appetite suppression alone.